Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis

NCT05523765 is registered in ClinicalTrials.gov with Priovant Therapeutics, Inc. as lead sponsor.

NCT NCT05523765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05523765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active Non-Infectious Intermediate-, Posterior-, and Panuveitis
Lead sponsor
Priovant Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 14, 2022
Completion date
July 30, 2024
Enrollment
26 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

non-infectious intermediate uveitis, non-infectious pan uveitis, non-infectious posterior uveitis